Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

Adverse Effect of Drugs and Medicaments in Therapeutic Use Clinical Trial

Official title: A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

Status Completed

Clinical Trial Summary

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

Clinical Trial Description

Participants will receive either the investigational drug (ATL-001) or Placebo (inactive substance). Neither the participant nor the Investigator will know to which of these study drug groups each participant has been assigned. In case of an emergency, however, the Investigator can get this information.

After a 30-day Screening period to confirm the eligibility, the prticipants will be treated for 5 days (the treatment period) and followed by 30 days of observation and assessment of treatment outcomes (the follow-up period). ;

Related Conditions & MeSH terms

• Adverse Effect of Drugs and Medicaments in Therapeutic Use

• NCT number: NCT05647343
• Study type: Interventional
• Source: Atlas Molecular Pharma
• Status: Completed
• Phase: Phase 1
• Start date: March 31, 2023
• Completion date: April 8, 2024